BAD

Across TCGA pan-cancer cohorts, BAD mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BAD data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher BAD mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated BAD expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, HNSC, and GBM are the cancer types where BAD mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.619	0.350	.004	18	view →
HNSC	DFS	Median	IV	1.000	0.413	.033	7	view →
GBM	OS	Tertile	All	0.907	0.732	.018	5	view →
UCEC	OS	Tertile	III,IV	0.335	1.000	.047	4	view →
LUAD	DFS	Median	III,IV	0.432	0.925	.047	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

BAD–PDAC (OS)

Open the PDAC breakdown →